© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

PharmaVitae: Stada Arzneimittel HC Slidepack 02/12 quality dataexpert analysisintuitive delivery the home of Business Intelligence

Stada prescription pharmaceutical performance, sales ($m) and growth rate (%), 2010–16

SWOT analysis of Stada Several patent expiries in the near-term coupled to strong foothold in yet immature generic markets to drive growth. Recent acquisition of Grunenthal and Spirig’s product portfolios to increase the proportion of revenues derived from higher margin branded products. Stada largely relies on external development collaborations in order to limit R&D costs and risks. Strengths German healthcare reform has intensified competitive and pricing pressures in Stada’s largest market in terms of revenues.. Weaknesses Profit growth through planned consolidation of manufacturing facilities and commercial operations (‘Build the future’ initiative expected to make biggest impact in 2012 and 2013). Further product acquisitions and in-licensing deals to expand regional portfolios. Decreasing reliance on sales of low-cost generics in increasingly competitive Western European markets, mainly through expansion in emerging Eastern European and RoW markets. Opportunities Potential introduction of stricter pricing regulations in emerging markets, such as Russia. Steepening competition among generic players during the patent cliff. Potential impact of a worsening economic and financial crises on the ability of European governments to meet their growing healthcare budgets. Threats

Corporate M&A and expansion strategy 2011 – acquisition of branded portfolio in Central and Eastern Europe and Middle East from Grünenthal 2007 – (M&A) British Forum Bioscience group and Russian MAKIZ group 2006 – (M&A) Serbian Hemofarm Group. Divested US subsidiary 2005 – (M&A) Ciclum Farma in Portugal, 58% stake in Chinese pharmaceutical manufacturer BCP and 97.5% stake in Russian Nizhpharm 2010 – acquisition of a range of local brands in Italy 2003 – (M&A) Schein Pharmaceuticals in the UK, acquisition of a 60% stake in Italian pharmaceutical sales company NPA and acquisition of German OTC brands from Redinomedica 2002 – (M&A) Mova Laboratories and inauguration of US subsidiary. (M&A) Bayvit and Ciclum Pharma in Spain, and acquisition of commercialization rights to a range of Spanish brands as well as Crinos’generic portfolio in Italy – start-up of biosimilars cooperation with DSM and (M&A) Croma Medic in the Philippines 2000 – (M&A) Clonmel Healthcare in Ireland 1999 – subsidiary in Thailand 1998 – (M&A) PharmaCoDane Aps in Denmark and acquisition of oncology brands from Fresenius in Germany 1996 – (M&A) Aliud Pharma in Germany and Czech Republic and EG Laboratoires Euro Generics in France 1992 – Hong Kong subsidiary 1991 – (M&A) Centrafarm in Netherlands and N.V Eurogenerics in Belgium 1986 – Helvepharm AG in Switzerland and Stada Arzneimittel in Austria

Stada prescription pharmaceutical performance, sales ($m) and growth rate (%), 2010–16

Branded and non-branded product sales ($m), 2010–16

Stada generic pharmaceutical absolute sales growth by therapy area($m), 2010–16

Stada generic pharmaceutical sales by therapy area ($m), 2010–16

Stada prescription pharmaceutical sales by geographic region ($m), 2010–16

Stada prescription pharmaceutical absolute sales growth by region($m), 2010–16

Stada prescription pharmaceutical sales by formulation ($m), 2010–16

© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor